clexane 60 mg fertigspritzen
mevita handels gmbh (4238046) - enoxaparin-natrium ((mw: ca. 4500)) - injektionslösung - enoxaparin-natrium ((mw: ca. 4500)) (24797) 60 milligramm
clexane
sanofi israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - clexane is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane forte
sanofi - aventis israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin - clexane forte is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary inte
clexane forte 12000iu(120mg)/0,8ml injekční roztok v předplněné injekční stříkačce
sanofi s.r.o., praha array - 9276 sodnÁ sŮl enoxaparinu - injekční roztok v předplněné injekční stříkačce - 12000iu(120mg)/0,8ml - enoxaparin
clexane forte 15000iu(150mg)/1ml injekční roztok v předplněné injekční stříkačce
sanofi s.r.o., praha array - 9276 sodnÁ sŮl enoxaparinu - injekční roztok v předplněné injekční stříkačce - 15000iu(150mg)/1ml - enoxaparin
clexane 2000 ui (20 mg)/0,2 ml
chinoin private co. ltd. - ungaria - enoxaparinum - sol. inj. in seringa preumpluta - 2000ui(20mg)/0,2ml - antitrombotice grupul heparinei
clexane 4000 ui (40 mg)/0,4 ml
chinoin private co. ltd. - ungaria - enoxaparinum - sol. inj. in seringa preumpluta - 4000ui(40mg)/0,4ml - antitrombotice grupul heparinei
clexane 6000 ui (60 mg)/0,6 ml
chinoin private co. ltd. - ungaria - enoxaparinum - sol. inj. in seringa preumpluta - 6000ui(60mg)/0,6ml - antitrombotice grupul heparinei
clexane 8000 ui (80 mg)/0,8 ml
chinoin private co. ltd. - ungaria - enoxaparinum - sol. inj. in seringa preumpluta - 8000ui(80mg)/0,8ml - antitrombotice grupul heparinei
clexane 8000iu(80mg)/0,8ml injekční roztok v předplněné injekční stříkačce
sanofi s.r.o., praha array - 9276 sodnÁ sŮl enoxaparinu - injekční roztok v předplněné injekční stříkačce - 8000iu(80mg)/0,8ml - enoxaparin